Panama City, Panama–(Newsfile Corp. – February 2, 2026) – HTX, a leading global cryptocurrency exchange, has announced the listings of CLAWNCH (Clawnch) and MOLT (Moltbook) on February 1. Spot trading for the CLAWNCH/USDT pair and the MOLT/USDT pair is now available to users on HTX. As two AI+Crypto projects within the Base ecosystem, Clawnch and […]

New York City, Feb. 02, 2026 (GLOBE NEWSWIRE) — BCKD Capital (“BCKD” / “The Firm“), a newly relaunched global hybrid financial firm based in New York City and Tokyo, is announcing its listing plans for both the financial firm and its newly formed multinational holding firm “SVCV“. The announcement comes ahead of its first fund,

BCKD Capital and SVCV Announce Listing Plans in Tokyo and Hong Kong Ahead of Its First Fund BCKD Capital and Multinational SVCV Announces Its First Fund and Listing Plans in Tokyo and Hong Kong GlobeNewswire February 02, 2026 New York City, Feb. 02, 2026 (GLOBE NEWSWIRE) — BCKD Capital (“BCKD” / “The Firm“), a newly

New York City, Feb. 02, 2026 (GLOBE NEWSWIRE) — BCKD Capital (“BCKD“), a newly relaunched global hybrid financial firm based in New York City and Tokyo, today announced the launch of its multinational holding company, SVCV (“The Group“). The launch marks a key milestone in BCKD Capital's global expansion strategy and its vision to build

SVCV to Launch as a Next-Generation Multinational Holding Company SVCV will market itself as a global cultural powerhouse GlobeNewswire February 02, 2026 New York City, Feb. 02, 2026 (GLOBE NEWSWIRE) — BCKD Capital (“BCKD“), a newly relaunched global hybrid financial firm based in New York City and Tokyo, today announced the launch of its multinational

(NASDAQ:MOLN),(SWX:MOLN.SW), Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors MP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026 Molecular Partners to host conference call February 2

(Paris:SAN), Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients with type 3 Gaucher disease (GD3), a rare lysosomal storage disorder Venglustat demonstrated superiority versus enzyme replacement therapy in addressing neurological

Press Release: Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease GlobeNewswire February 02, 2026 Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 GlobeNewswire February 02, 2026 Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors

Enjoy Exclusive Disney Tsum Tsum Collectibles and Tax-Absorbed Shopping Privileges The Shilla Duty Free welcomes the Year of the Horse with a lineup of Lunar New Year travel retail initiatives, led by its exclusive partnership as the Official Beauty Travel Retail Partner of Mandopop artist Silence Wang’s (æ±è’æ³-) Singapore concerts, followed by the first collaboration